scholarly journals A rat model of chronic kidney disease-mineral bone disorder

2009 ◽  
Vol 75 (2) ◽  
pp. 176-184 ◽  
Author(s):  
Sharon M. Moe ◽  
Neal X. Chen ◽  
Mark F. Seifert ◽  
Rachel M. Sinders ◽  
Dana Duan ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Rat Model ◽  
Mineral Bone Disorder ◽  
Bone Disorder

scholarly journals Newly Developed Rat Model of Chronic Kidney Disease–Mineral Bone Disorder

2018 ◽  
Vol 25 (2) ◽  
pp. 170-177 ◽  
Author(s):  
Kentaro Watanabe ◽  
Hideki Fujii ◽  
Shunsuke Goto ◽  
Kentaro Nakai ◽  
Keiji Kono ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Rat Model ◽  
Mineral Bone Disorder ◽  
Bone Disorder

scholarly journals R-568 reduces ectopic calcification in a rat model of chronic kidney disease-mineral bone disorder (CKD-MBD)

2009 ◽  
Vol 24 (8) ◽  
pp. 2371-2377 ◽  
Author(s):  
S. M. Moe ◽  
M. F. Seifert ◽  
N. X. Chen ◽  
R. M. Sinders ◽  
X. Chen ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Rat Model ◽  
Ectopic Calcification ◽  
Mineral Bone Disorder ◽  
Bone Disorder

Potential effect of pharmaceutical care to improve outcomes in patients with chronic kidney disease-mineral bone disorder in Sulaimani dialysis centers

2020 ◽  
pp. 82-94
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Pharmaceutical Care ◽  
Biochemical Parameters ◽  
Positive Impact ◽  
Potential Effect ◽  
Care Group ◽  
Mineral Bone Disorder ◽  
Bone Disorder

Objective: the present study was aimed to evaluate the role of pharmaceutical services in improving the outcome of mineral bone disorder in patients with advanced chronic kidney disease. Methodology: One hundred and twenty patients with chronic kidney disease-mineral bone disorder (CKD-MBD) screened for eligibility, seventy-six patients enrolled in the study and randomly allocated into two groups: pharmaceutical care and usual care, both groups interviewed by the pharmacist using specific questionnaire for assessing the quality of life (QoL). All the drug related problems (DRPs) including drug-drug interactions (DDIs) were recorded by the pharmacist. Blood samples were collected and utilized for analyzing the levels of vitamin D, phosphorous, calcium, albumin and parathyroid hormone at baseline and three months after. The pharmaceutical care group received all the educations about their medications and how to minimize DRPs; improve the QoL. Additionally, the pharmaceutical intervention included correcting the biochemical parameters. Results: Pharmaceutical care significantly improved patients QoL and minimized DRPs and DDIs. It was also effective in improving the biochemical parameters. Conclusion: Pharmaceutical care has a positive impact on improving the outcome of patients with CKD-MBD through attenuating DRPs, improving the biochemical parameters and the QoL.

Chronic Kidney Disease–Mineral-Bone Disorder: A New Paradigm

2007 ◽  
Vol 14 (1) ◽  
pp. 3-12 ◽  
Author(s):  
Sharon M. Moe ◽  
Tilman Drüeke ◽  
Norbert Lameire ◽  
Garabed Eknoyan
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
New Paradigm ◽  
Mineral Bone Disorder ◽  
Bone Disorder

scholarly journals Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis

2018 ◽  
Vol 34 (1) ◽  
pp. 107-115 ◽  
Author(s):  
Marciana Laster ◽  
Melissa Soohoo ◽  
Elani Streja ◽  
Robert Elashoff ◽  
Stephanie Jernigan ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Ethnic Differences ◽  
Mineral Bone Disorder ◽  
Bone Disorder ◽  
Racial Ethnic
Sign in / Sign up

Export Citation Format

Share Document